BC
VRTX icon

Barnett & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Barnett & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17
Closed -$4K – 263
2021
Q4 		$4K Buy
+17
New +$3.31K ﹤0.01% 251

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Barnett & Company's VRTX Position: Q1 2022 in Review

Barnett & Company sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 17 shares — an estimated $4K sold.

Barnett & Company first reported a position in VRTX in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • Barnett & Company reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Barnett & Company sold 17 Vertex Pharmaceuticals shares in Q1 2022, an estimated $4K.
  • Barnett & Company first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Barnett & Company's Vertex Pharmaceuticals position peaked at $4K in Q4 2021.
  • 1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Barnett & Company's 13F filing for Q1 2022, filed 28 Apr 2022.